Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ENLIVEN THERAPEUTICS INC (ELVN) Stock Price & Overview
NASDAQ:ELVN • US29337E1029
Current stock price
41.7 USD
+0.47 (+1.14%)
At close:
41.7 USD
0 (0%)
After Hours:
The current stock price of ELVN is 41.7 USD. Today ELVN is up by 1.14%. In the past month the price increased by 7.39%. In the past year, price increased by 103.32%.
ELVN Key Statistics
52-Week Range14.785 - 48.53
Current ELVN stock price positioned within its 52-week range.
1-Month Range38.74 - 48.53
Current ELVN stock price positioned within its 1-month range.
- Market Cap
- 2.494B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.86
- Dividend Yield
- N/A
ELVN Stock Performance
Today
+1.14%
1 Week
-5.76%
1 Month
+7.39%
3 Months
+57.66%
Longer-term
6 Months +78.05%
1 Year +103.32%
2 Years +84.76%
3 Years +127.87%
5 Years N/A
10 Years N/A
ELVN Stock Chart
ELVN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ELVN. When comparing the yearly performance of all stocks, ELVN is one of the better performing stocks in the market, outperforming 94.32% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. ELVN has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ELVN Earnings
Next Earnings DateMay 20, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported-$0.48
Revenue Reported
EPS Surprise -24.57%
Revenue Surprise -100.00%
ELVN Forecast & Estimates
16 analysts have analysed ELVN and the average price target is 52.02 USD. This implies a price increase of 24.75% is expected in the next year compared to the current price of 41.7.
For the next year, analysts expect an EPS growth of -14.61% and a revenue growth -100% for ELVN
Analysts
Analysts85
Price Target52.02 (24.75%)
EPS Next Y-14.61%
Revenue Next Year-100%
ELVN Index Membership
ELVN is currently included in the following stock indexes tracked on ChartMill.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 1.59% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-103.69M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.78% | ||
| ROE | -22.56% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-4.35%
Sales Q2Q%N/A
EPS 1Y (TTM)1.59%
Revenue 1Y (TTM)N/A
ELVN Ownership
Ownership
Inst Owners92.87%
Shares59.80M
Float46.55M
Ins Owners8.34%
Short Float %11.54%
Short Ratio4.45
ELVN Industry Overview
ELVN operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
ELVN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELVN
Company Profile
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 60 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
IPO: 2020-03-12
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 60
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What does ELVN do?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 60 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
What is the current price of ELVN stock?
The current stock price of ELVN is 41.7 USD. The price increased by 1.14% in the last trading session.
What is the dividend status of ENLIVEN THERAPEUTICS INC?
ELVN does not pay a dividend.
How is the ChartMill rating for ENLIVEN THERAPEUTICS INC?
ELVN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for ENLIVEN THERAPEUTICS INC?
ENLIVEN THERAPEUTICS INC (ELVN) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for ENLIVEN THERAPEUTICS INC?
ENLIVEN THERAPEUTICS INC (ELVN) will report earnings on 2026-05-20.
What is the Short Interest ratio of ENLIVEN THERAPEUTICS INC (ELVN) stock?
The outstanding short interest for ENLIVEN THERAPEUTICS INC (ELVN) is 11.54% of its float.